Vivos Therapeutics, Inc. - 8-K Filing
Vivos Therapeutics entered into an Exchange Agreement with Streeterville Capital, LLC to exchange $8.2 million in debt for equity, including preferred shares and common stock, contingent on raising at least $2.6 million by June 15, 2026. The company also issued a $5 million unsecured convertible note to V-Co Investors 4 LLC as part of an effort to raise up to $5.5 million in equity financing before June 30, 2026. Additionally, the firm received notice from Nasdaq that its stock is below the minimum bid price requirement for continued listing and has until December 2, 2026, to regain compliance... (Items: 1.01 Entry into a Material Definitive Agreement, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, 3.02 Unregistered Sales of Equity Securities, 9.01 Financial Statements and Exhibits)
Tickers: $VVOS